Skip to main content
Premium Trial:

Request an Annual Quote

Detroit R&D Receives $850K from NIH to Develop Recombinant Antibodies, Antibody Array

NEW YORK, Oct. 7 (GenomeWeb News) - Detroit R&D recently received a $100,000 Phase I Small Business Innovation Research award from the National Institutes of Health to fund the production of single-chain recombinant antibodies for early detection of cancer.


In addition, the company received a $750,000 Phase II SBIR award to develop antibody microarrays to screen drug-metabolizing enzymes.


Previously, Detroit R&D had received six SBIRs to develop technology for studying hypertension, COX-2-dependent DNA damage, and drug screening. In addition, the company currently has two active Phase I SBIRs in breast cancer and fetal alcohol syndrome and one active Phase II SBIR in drug metabolism of frog embryos.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.